Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United States
/
Pharmaceuticals & Biotech
Create a narrative
Amylyx Pharmaceuticals Community
NasdaqGS:AMLX Community
1
Narratives
written by author
1
Comments
on narratives written by author
17
Fair Values set
on narratives written by author
Create a narrative
Amylyx Pharmaceuticals
Popular
Undervalued
Overvalued
Community Investing Ideas
Amylyx Pharmaceuticals
AN
AnalystConsensusTarget
Consensus Narrative from 5 Analysts
Avexitide Launch In 2027 Will Strengthen Our Pipeline
Key Takeaways Strategic developments in the pipeline and collaborations aim to address unmet medical needs and present long-term revenue growth opportunities. Robust financing extends cash runway, supporting ongoing R&D and potentially optimizing net margins through efficient resource allocation.
View narrative
US$8.80
FV
50.6% undervalued
intrinsic discount
-50.39%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
16
users have followed this narrative
14 days ago
author updated this narrative
Your Valuation for
AMLX
AMLX
Amylyx Pharmaceuticals
Your Fair Value
US$
Current Price
US$4.35
n/a
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-492m
398m
2015
2018
2021
2024
2025
2027
2030
Revenue -US$22.5m
Earnings -US$3.3m
Advanced
Set Fair Value